Safety and efficacy of prone percutaneous nephrolithotomy (PCNL) in morbidly obese patients.

Musab Umair Khalid¹, Muhammad Nawaz², Muhammad Usman Javed³, Khubaib Shahzad⁴, Hussain Ahmad⁵, Zahoor Iqbal Mirza⁶

ABSTRACT... Objective: To present our experience regarding the safety and efficacy of prone PCNL in morbidly obese patients. Study Design: Observational study. Setting: Armed Forces Institute of Urology, Rawalpindi. Period: February 2018 to February 2020. Material & Methods: After applying inclusion and exclusion criteria, a total of 47 morbidly obese patients undergoing PCNL in prone position were observed prospectively. The demographic data, intraoperative and postoperative outcomes were evaluated. The data were analyzed by SPSS ver. 24. Results: Average age was (46.43±10.41) years with (70.2%) males and (29.8%) females. The mean basal metabolic index (BMI) is (40.47±3.37) kg/m² and mean stone size was (2.93±0.49 mm). A single stone is seen in twelve patients (25.5%), multiple in sixteen (34.0 %), partial staghorn in nine (19.1 %) and complete staghorn calculus in ten (21.3%) patients. The mean operative time was (83.38±13.20 min), duration of hospital stay (55.94±16.52 hours), stone-free rate (72.3%) and only (27.7%) patients had re-intervention. Calcium oxalate is the most common stone encountered followed by calcium phosphate and uric acid. Intraoperatively, transfusion secondary to bleeding and postoperatively grade 3 clavien-dindo classification is most commonly seen. Conclusion: Prone PCNL is an effective and safe procedure for morbidly obese patients.

Key words: Morbidly Obese PCNL, Prone PCNL Obesity, Renal Calculus Prevalence, Renal Calculus Composition.

INTRODUCTION

Obesity is the leading cause of morbidity and mortality with a prevalence of (53.1%) in European countries.¹ The risk factors for urolithiasis is related to the comorbidities associated with obesity such as hypertension, diabetes mellitus and hyperlipidemia.²,³

The prevalence of urolithiasis in Asia is 1%–19.1% while it is 16% in Pakistan.⁴,⁵ Percutaneous nephrolithotomy (PCNL) is the first line treatment for renal calculi ≥2 cm.⁶,⁷ Since obesity is already expected to become a global epidemic, an increased number of obese patients with complex nephrolithiasis in need of treatment are expected.⁸

In 2012, the CROES PCNL global study showed that PCNL may be done safely in obese patients but with a longer operation time, lower stone free rates and higher re-intervention rates.⁹ In seventeen super obese patients, prone PCNL were performed by Keheila M. et al¹⁰ and concluded that PCNL is safe and feasible in super obese.

Being a high volume referral tertiary care center, we have collected data of morbidly obese patients (BMI >35kg/m²) in order to provide the first documented prone PCNL outcome study for patients stratified by basal metabolic index (BMI) in the region. The aim is to determine the safety and efficacy of prone PCNL in morbidly obese patients.

MATERIAL & METHODS

After getting approval from institutional review board (Uro-adm-Trg-1/IRB/2020/109) an observational study was conducted at Armed Forces Institute of Urology (AFIU), Rawalpindi.
Prone Percutaneous Nephrolithotomy (PCNL)

where 47 morbidly obese patients undergoing PCNL in the prone position from February 2018 to February 2020 were reviewed prospectively.

Patients with BMI more than >35kg/m², all the adult (20-80 years) patients of either gender with renal calculi of >20 mm in size, American society of anesthesiologists [ASA] score 2–3, Any systemic co-morbid disease and no active urinary tract infection (assessed on urinalysis).

Exclusion criteria for this study included: congenital kidney anomalies, previous urological surgery (assessed on history), patients with recurrent stone, pregnancy (assessed on ultrasonography (USG)), pelvis kidney (assessed on USG), pelvis-ureteric junction obstruction (assessed on USG and Intravenous urography (IVU)), sepsis and bleeding disorders (INR >1.2).

Preoperative evaluation of the patients included age, gender, BMI, type and size of stone. Intraoperative and postoperative data contain no of tract dilated, operative time, duration of hospital stay, the need for the second procedure (either PCNL or ESWL), stone composition, stone-free status and intraoperative /postoperative complications (Clavien-Dindo classification). Operative time elapsed from the induction of anesthesia until extubation. Stone free rate was defined as no stone or clinically insignificant residual fragment of less than 4mm.

General anesthesia is preferred. Antibiotics with (cefaparazone and sulbactam) were given at the time of induction of anesthesia. During the procedure, the patient is initially placed in lithotomy position, draped and ureterorenoscope introduced in the patient’s urethra. Ureteral orifice was identified and a 4fr open ended ureteral catheter is then advanced up the kidney. A 16Fr Foley catheter is secured alongside the 4Fr open ended catheter to keep the bladder compressed. A 60m/l leur lock syringe is filled with the contrast and connected to the open ended catheter.

A retrograde pyelogram is obtained and under C-arm fluoroscopy, the preferred calyx is selected and chiba needle (20cm) advanced into the tissues. Successful penetration is confirmed by return of urine. A sensor guide wire is advanced into the pelvi-calyceal system. A small nick is made in the skin and tract is dilated through 10F fascial dilator. An amplatz sheath (30 Fr) is pushed forward over the fascial dilator and guide wire into the determined calyx.

A rigid nephroscope (12 Fr) is introduced into the collecting system, calculus is identified and fragmented using a pneumatically driven EMS Swiss lithoclast. The fragments are removed using suction and irrigation. Stone free status is ensured through visual and fluoroscopic inspection. If a residual calculus is seen in the line of ureter, a 4.8 Fr 26 cm double J ureteral stent is placed.

All patients had postoperative X-Ray kidney, ureter and bladder (KUB) after 24 hours and computed tomography of kidney, ureter and bladder (CT KUB) scans at 3 months to determine stone-free rates. The data was analyzed by SPSS ver. 24. Age, BMI, stone size, intrapartum and postpartum complications (Clavien-Dindo classification). Operative time elapsed from the induction of anesthesia until extubation. Stone free rate was defined as no stone or clinically insignificant residual fragment of less than 4mm.

The systemic diseases associated with morbid obesity are type 2 diabetes mellitus 5 (10.6%), hypertension 9 (19.1%), ischemic heart disease 7 (14.9%), osteoarthritis 5 (10.6%) and sleep apnea 5 (10.6%), gastroesophageal reflux disease 7 (14.9%), infertility 7 (14.9%) and depression 2 (4.3%). Intra-operative and post-operative characteristics and complications were given in
Table-I to III.

| Characteristics          | Mean ± SD  | N, Percentage (%) |
|--------------------------|------------|-------------------|
| Operation Time (min)     | 83.38±13.20|                   |
| Duration of Hospital Stay (hours) | 55.94±16.52|                   |
| Stone Free Status        | 34/47(72.3%)|                   |
| Re-intervention          | 13/47, (27.7%)|                 |
| 1. PCNL                  | 4/47 (8.5%)|                   |
| 2. ESWL                  | 9/47 (19.1%)|                   |
| Stone Composition        | 47 PCNL    |                   |
| 1. Calcium oxalate       | 20, (42.6%)|                   |
| 2. Calcium phosphate     | 12, (25.5%)|                   |
| 3. Uric Acid             | 10, (21.3%)|                   |
| 4. Struvite              | 5, (10.6%) |                   |
| Dilated Tract            | 47 PCNL    |                   |
| Single tract             | 33, (70.2%)|                   |
| More than one tract      | 14, (29.8%)|                   |

**Table-I. Intra-operative and post-operative characteristics.**

| Complication                      | N (% total intraoperative complications) |
|-----------------------------------|----------------------------------------|
| Renal collecting system injury    | 3 (30%)                                |
| Violation of the pleural space    | 2 (20%)                                |
| Transfusion                       | 5 (50%)                                |
| Colonic injury                    | 0                                      |
| Mortality                         | 0                                      |

**Table-II. Intra-operative complications.**

| Grade | N (% total postoperative complications) |
|-------|----------------------------------------|
| 1     | 2 (11.1%)                              |
| 2     | 3 (16.7%)                              |
| 3     | 13 (72.2%)                             |
| 4     | 0                                      |
| 5     | 0                                      |

**Table-III. Postoperative complications based on clavien-dindo classification.**

**DISCUSSION**

One of the causes of global increase in the prevalence of urolithiasis is high BMI. Urolithiasis is associated with obesity, diabetes, hyperuricemia, hyperlipidemia and hypertension. Therefore, diet and lifestyle changes are advised for the prevention. Shavit, et al. reported the incidence of urolithiasis is higher in overweight and obese patients.

Matta I, et al. and Falahatkar S, et al. reported the increased incidence of urolithiasis in morbidly obese females as compared to males (57.14% vs 42.86%) and (52% vs 48%) respectively. While prevalence of urolithiasis is more in morbidly obese men (70.2% vs 29.8%) in our study and a study by Chen TF, et al. The mean BMI was lower (34.47 kg/m²) in a study by Falahatkar S, et al. and higher (57.2kg/m²) by Keheila M, et al. as compared to our study (40.47kg/m²).

The outcome of PCNL not only depends on the stone size but also on the stone complexity. A study by Alyami FA, et al. estimated the mean stone size (2.4 ±0.39 cm) while we had encountered significantly large calculi with a mean stone size of (2.93±0.49 cm). Keheila M, et al. managed the full staghorn in six patients and partial in four patients. A study by Matta I, et al. operated the (35.7%) of the staghorn calculi, Chen TF, et al. demonstrated (42%) of partial and (13%) of complete staghorn calculi while our study had partial staghorn in nine (19.1%) and complete staghorn calculus in ten (21.3%) patients. It shows the most pressing need for early diagnosis and immediate intervention in morbidly obese patients with renal calculi.

The most common systemic condition associated with morbid obesity and urolithiasis is hypertension in our study (19.1%) and Keheila M, et al. reported it to be (70%). The mean operative time in our study is less (83.38±13.20 min). It was much higher (106 min) in a study by Keheila M, et al. and (96.80±29.66 min) by Falahatkar S, et al. Our mean operative time was consistent with supine PCNL (79.38±38.38 min) by Falahatkar S, et al. It is potentially an advantage for morbidly obese patients due to lesser anesthesia time even in prone position.

The mean hospital stay in our study was (55.94±16.52 hours) and the study by Falahatkar S, et al. (54.06 ± 14.34) hours in the prone versus (58.33 ± 13.80) hours in the supine position. Chen TF, et al. reported it to be six...
days. This is partially due to the fact that most of the patients in our hospital have the right to obtain free health care services. Therefore, special attention is given to quick postoperative recovery. This will guarantee the best possible treatment at a reasonably lower cost.

The stone clearance rate in our study was 72.3%. Chen TF, et al.\(^\text{17}\) shows the 70% clearance while Falahatkar S, et al.\(^\text{16}\) had 78% and 73.3% in the prone and the supine positions, respectively. Alyami FA, et al.\(^\text{18}\) showed the stone clearance rate of 80% while Manohar T, et al.\(^\text{19}\) showed it to be 95% due to simultaneous ureteroscopy and flexible nephrosopes to access inaccessible calices. Re-intervention in the form of PCNL in obese (BMI 30-39kg/m\(^2\)) is seen in 12.1% of the patients by Alyami FA, et al.\(^\text{18}\) while none of the morbid obese had the second intervention in the form of PCNL. ESWL is performed in 34% of patients and 40% of the patients in obese and morbid obese respectively by Alyami FA, et al.\(^\text{18}\) Our study showed a statistically better results in terms of ESWL (19.1%) but the rate of PCNL re-intervention is much higher (8.5%).

The stone composition in our study were calcium oxalate (42.6%), calcium phosphate (25.5%), uric acid (21.3%) and struvite (10.6%). A study by Almannie RM, et al.\(^\text{20}\) estimated that most of the stones were calcium oxalate (61.3%), carbonate apatite (27.7%), and uric acid (7.3%) stones in 137 overweight patients. The results of tract dilatation in our study (single vs multiple) were consistent with a study by Keheila M, et al.\(^\text{10}\)

The most common intraoperative complication was bleeding which was managed by transfusion. Renal collecting system injury was managed successfully by nephrostomy drainage for 5 days and DJ-stent placement for 4 weeks. The violation of the pleural space was managed by placing a chest drainage tube immediately at the end of operation. Postoperatively, two patients had Grade 1 Clavien-Dindo complication in our study. Three (6.4%) out of forty-seven patients had sepsis/systemic inflammatory response syndrome which is managed conservatively with intravenous broad spectrum antibiotics. Re-intervention in the form of PCNL or ESWL is required in thirteen patients (27.7%). All the patients had complete stone clearance after re-intervention. Keheila M, et al.\(^\text{10}\) Reported the re-intervention rate (26.6%). This study is retrospective and contains a small number of cases. While we had observed the safety and efficacy of prone PCNL prospectively with a significantly large cohort size.

A study by Chen TF, et al.\(^\text{17}\) reported the fever (17%) while Manohar T, et al.\(^\text{19}\) showed infection (18%) as the most prevalent complication. The former study is retrospective with lack of morbidly obese patients. The low intraoperative and postoperative complication rates in our study showed the prone PCNL in morbidly obese patients is safe and effective.

It was a single center study observed in prone position only. The comparison of the outcomes between different positions and centers has been limited. Despite these limitations, it is the largest single center study in region providing data for morbidly obese patients with renal calculus.

**CONCLUSION**

The present study showed that prone PCNL in morbidly obese patients is effective and safe. It will allow urologists to perform prone PCNL in morbidly obese patients.

**REFERENCE**

1. Marques A, Peralta M, Naia A, Loureiro N, de Matos MG. Prevalence of adult overweight and obesity in 20 European countries, 2014. The European Journal of Public Health. 2018 Apr 1; 28(2):295-300.

2. Ozgor F, Kucuktopcu O, Ucpinar B, Yanaral F, Binbay M. Skin to calyx distance is not a predictive factor for miniaturized percutaneous nephrolithotomy outcomes. International braz j urol. 2017 Aug; 43(4):679-85.

3. Huynh LM, Huang E, Patel RM, Okhunov Z. Predictability and practicality of image-based scoring systems for patient Assessment and outcome stratification during percutaneous nephrolithotomy: A contemporary update. Current urology reports. 2017 Dec 1; 18(12):95.
4. Liu Y, Chen Y, Liao B, Luo D, Wang K, Li H, et al. Epidemiology of urolithiasis in Asia. Asian journal of urology. 2018 Oct 1; 5(4):205-14.

5. Memon A, Anwar K, Orakzai N, Ather MH, Biyabani SR, Nasir AR, et al. Epidemiology of stone disease in Pakistan. InUrolithiasis 2012 (pp. 21-38). Springer, London.

6. Tailly T, Denstedt J. Innovations in percutaneous nephrolithotomy. International Journal of Surgery. 2016 Dec 1; 36:665-72.

7. Torricelli FC, Monga M, Dall'Aqua V, Marchini GS, Vicentini FC, Danilovic A, et al. Percutaneous Nephrolithotomy in Immunocompromised Patients: Outcomes from a matched case–control study. Journal of Endourology. 2016 Dec 1; 30(12):1326-31.

8. Bayne DB, Usawachintachit M, Tzou D, Taguchi K, Shindel A, Chi TL. Increasing body mass index steepens the learning curve for ultrasound-guided percutaneous nephrolithotomy. Urology. 2018 Oct 1; 120:68-73.

9. Fuller A, Razvi H, Denstedt JD, Nott L, Pearle M, Cauda F, et al. CROES PCNL Study Group. The CROES percutaneous nephrolithotomy global study: the influence of body mass index on outcome. The Journal of urology. 2012 Jul 1; 188(1):138-44.

10. Keheila M, Leavitt D, Galli R, Motamedinia P, Theckumparampil N, and Siev M, et al. Percutaneous nephrolithotomy in super obese patients (body mass index≥ 50 kg/m2): Overcoming the challenges. BJU international. 2016 Feb 1; 117(2):300-6.

11. Strohmaier WL, Wrobel BM, Schubert G. Overweight, insulin resistance and blood pressure (parameters of the metabolic syndrome) in uric acid urolithiasis. Urological research. 2012 Apr 1; 40(2):171-5.

12. Abate N, Chandalia M, Cabo-Chan Jr AV, Moe OW, Sakhae K. The metabolic syndrome and uric acid nephrolithiasis: novel features of renal manifestation of insulin resistance. Kidney international. 2004 Feb 1; 65(2):386-92.

13. Takeuchi H, Aoyagi T. Clinical characteristics in urolithiasis formation according to body mass index. Biomedical reports. 2019 Jul 1; 11(1):38-42.

14. Shavit L, Ferraro PM, Johri N, Robertson W, Walsh SB, Mochchala S, et al. Effect of being overweight on urinary metabolic risk factors for kidney stone formation. Nephrology Dialysis Transplantation. 2015 Apr 1; 30(4):607-13.

15. Immad MI, Jabbour T, Zgheib J, et al. Prone PCNL: Safety and efficacy in obese and morbidly obese patients. Urol Nephrol Open Access J. 2018; 6(3):84-88.

16. Khoshrang H, Falahatkar S, Ilat S, Akbar MH, Shakiba M, Farzan A, et al. Comparative study of hemodynamics electrolyte and metabolic changes during prone and complete supine percutaneous nephrolithotomy. Nephro-urology monthly. 2012; 4(4):622.

17. Chen TF, Chen CH, Lee YJ. The role of body mass index predicting outcome of percutaneous nephrolithotomy. Urological Science. 2018 Sep 1; 29(5):252.

18. Alyami FA, Skinner TA, Norman RW. Impact of body mass index on clinical outcomes associated with percutaneous nephrolithotomy. Canadian Urological Association Journal. 2013 Mar; 7(3-4):E197.

19. Manohar T, Jain P, Desai M. Supine percutaneous nephrolithotomy: Effective approach to high-risk and morbidly obese patients. Journal of endourology. 2007 Jan 1; 21(1):44-9.

20. Almannie RM, AL-Nasser KA, Al-Barraq KM, Alsheheli MM, Al-Hazmi HH, Binsaleh SA, et al. The effect of the body mass index on the types of urinary tract stones. Urology Annals. 2020 Jan; 12(1):42.
**AUTHORSHIP AND CONTRIBUTION DECLARATION**

| No. | Author(s) Full Name       | Contribution to the paper                                                                 | Author(s) Signature |
|-----|---------------------------|-------------------------------------------------------------------------------------------|---------------------|
| 1   | Musab Umair Khalid        | Conception or design of the work.                                                          |                     |
| 2   | Muhammad Nawaz            | Acquisition and analysis.                                                                   |                     |
| 3   | Muhammad Usman Javed      | Drafting the work.                                                                         |                     |
| 4   | Khubaib Shahzad           | Revising it critically for important intellectual content.                                 |                     |
| 5   | Hussain Ahmad             | Final approval of the version to be published.                                             |                     |
| 6   | Zahoor Iqbal Mirza        | Accountable for all aspects of the work related to the accuracy.                           |                     |